ProQR Therapeutics (NASDAQ:PRQR) announces that its sepofarsen (QR-110) drug candidate for the treatment of Leber’s congenital amaurosis 10 (LCA10), was granted access to the PRIority MEdicines (PRIME) program by the European Medicines Agency (EMA).
This is the first EMA PRIME access received by the Company for its portfolio of RNA product candidates for inherited retinal diseases.
Shares are up 5% premarket.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.